Search Bar & Filters
Found 17 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of fenfluramine hydrochloride compared to a placebo in people with Rett syndrome, a genetic neurological disorder. This Phase 3 clinical trial aims to assess how well fenfluramine hydrochloride works and its safety in improving symptoms of Rett syndrome, with outcomes measured by changes in behavior and clinical impressions over 14 weeks. Participants receive fenfluramine hydrochloride or placebo orally during a 14-week double-blind period, including dose adjustment and maintenance. After this, all participants enter a 2-week transition period, then a 52-week open-label phase where they receive fenfluramine hydrochloride. Those who stop treatment without continued access undergo an 8-day medication taper and a 26-week follow-up. Throughout the trial, participants undergo assessments including questionnaires on behavior, sleep, communication, and caregiver impressions, as well as heart monitoring via ECG and echocardiograms to watch for side effects. Safety and adverse events are tracked up to nearly four years. The study involves regular visits during treatment and follow-up periods, aiming to measure changes in Rett syndrome symptoms and overall clinical status.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effect of a transdermal formulation called SFG-02 on Bladder Voiding Efficiency BVE in adults with Underactive Bladder UAB. This Phase 2a proof-of-concept study aims to assess both the impact on bladder function and the safety of the treatment compared to a placebo. Participants have symptoms like urinary hesitancy, straining to void, or weak urinary stream and meet specific bladder function criteria. Participants will undergo a 4-week placebo run-in period followed by 8 weeks of daily application of either the SFG-02 patch or a placebo patch. Each patch is worn for a full day, and participants will apply a new patch every day for a total treatment duration of 12 weeks. The study uses a randomized, double-blind design to compare the active drug to placebo. During the study, participants will visit the clinic every 2 to 4 weeks for checkups and tests. They will keep diaries to record bladder symptoms and the timing of patch changes. Researchers will monitor changes in Bladder Voiding Efficiency from baseline to the end of treatment as the primary outcome. Safety will also be assessed through laboratory tests and heart monitoring, with the entire participation lasting approximately 12 weeks.
Actively Recruiting
Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of brenipatide alongside standard of care SoC compared to a placebo plus SoC in adult participants with major depressive disorder. This Phase 3 trial aims to delay the return of major depressive symptoms and is sponsored by Eli Lilly and Company. Participants will be randomly assigned to receive one of three doses of brenipatide or a placebo, all administered by subcutaneous injection in addition to their standard treatment. The study includes a screening period lasting about one month, followed by a treatment period and potential post-treatment phase that together last at least 12 months. Throughout the trial, participants will self-inject the study medication and complete electronic and paper diaries along with questionnaires. Researchers will monitor the time to relapse of major depressive disorder and assess changes in depression rating scales, body weight, functional impairment, anxiety, quality of life, and other patient-reported outcomes. The follow-up period after treatment will last approximately 2 months.
Actively Recruiting
Researchers are evaluating the safety, tolerability, effectiveness, and how the body processes a drug called JNT-517 in children, adolescents, and adults who have phenylketonuria, a condition affecting phenylalanine levels in the body. This Phase 3 study aims to understand the impact of JNT-517 on managing phenylalanine levels and related symptoms in people with this condition. Participants will be randomly assigned to receive either JNT-517 or a matching placebo orally twice daily for an initial 6-week period. After this, eligible participants will continue with JNT-517 treatment for an additional 46 weeks, with dosing based on age. This study includes two treatment periods a blinded 6-week phase followed by an open-label 46-week phase where all participants receive JNT-517. During the study, participants will undergo regular assessments including measurement of plasma phenylalanine levels at various timepoints, evaluations of attention-related symptoms, dietary intake monitoring, and safety evaluations. Researchers will track changes in phenylalanine from baseline through week 6 and week 52, as well as treatment-emergent adverse events. The total participation duration includes 6 weeks of blinded treatment plus 46 weeks of open-label treatment, with ongoing monitoring throughout.
Actively Recruiting
Researchers are evaluating the medicine orforglipron compared to dulaglutide in children and teenagers aged 10 to less than 18 years who have type 2 diabetes. The study aims to understand how well these medicines work, how safe they are, and how the body processes them. This trial is a Phase 3 randomized study that focuses on treatment for pediatric participants with this condition. Participants will be randomly assigned to receive either orforglipron orally once daily or dulaglutide by subcutaneous injection once weekly. The study treatment period lasts about 40 weeks, with monitoring extending up to 61 weeks. Both medicines are being assessed for their effects on blood sugar control and other health measures during this time. Participants will be involved in regular visits for evaluations, including blood tests to measure hemoglobin A1c and other health indicators such as body weight, blood pressure, and cholesterol. Researchers will also monitor safety and how the medicines are processed in the body. Overall participation in the study will last approximately 61 weeks, during which participants will receive ongoing assessments to track treatment outcomes.
Actively Recruiting
Researchers are evaluating the effectiveness and safety of orforglipron in adult women with stress urinary incontinence SUI who are overweight or have obesity. SUI is characterized by leaking urine during activities such as coughing or exercising. This phase 3 study aims to compare orforglipron to a placebo in this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo orally. The study follows a parallel design with double masking and includes two independent groups. Treatment and assessments will occur over approximately 58 weeks, including screening, treatment, and safety follow-up. During the trial, participants will undergo evaluations to measure changes in the frequency of incontinence episodes, body weight, quality of life specific to urinary incontinence, use of continence pads, patient impression of condition, cholesterol levels, and waist circumference from baseline to week 52. Safety monitoring will continue through the follow-up period to assess any treatment-related effects.
Actively Recruiting
Researchers are evaluating the efficacy and safety of a fixed combination of follitropin alfa and lutropin alfa compared to human menopausal gonadotropin hMG in Japanese women with luteinizing hormone LH and follicle stimulating hormone FSH deficiency undergoing assisted reproductive technology ART. The study focuses on women who are premenopausal and wish to conceive, addressing fertility challenges related to these hormone deficiencies. This is a Phase 3 interventional trial with a randomized, parallel-group design. Participants will be assigned to one of two groups one receiving a fixed combination of recombinant follitropin alfa and lutropin alfa in a 21 ratio, and the other receiving hMG. Both treatments are administered daily by subcutaneous injection during ovarian stimulation, up to 18 days. Additional medications include daily cetrorelix acetate starting on Day 5 or 6 of stimulation to prevent premature ovulation, and coriongonadotropin alfa for final follicular maturation. After oocyte retrieval, participants will self-administer progesterone gel intravaginally for luteal phase support. During the study, participants will undergo assessments such as ultrasound scans to monitor follicle development, hormone level evaluations, and semen analysis of the male partner. Researchers will track the total number of oocytes retrieved, dosage and duration of gonadotropin treatment, embryo development, pregnancy rates, and safety outcomes including adverse events and ovarian hyperstimulation syndrome. The total study duration is about 5.5 months for those not becoming pregnant and up to 13 months for those with confirmed pregnancy.
Actively Recruiting
Researchers are studying geographic atrophy GA secondary to age-related macular degeneration AMD to understand how different doses of the drug FWY003 affect the condition. This randomized, double-masked, multi-center study aims to characterize the dose-response relationship, as well as assess the efficacy and safety of FWY003 compared to a placebo in adults aged 50 and older with GA due to AMD. Participants are randomly assigned to receive one of three dose levels of FWY003 or a placebo. The study drug or placebo is administered as part of a controlled treatment plan over an 18-month period. The trial includes multiple study groups to compare effects across doses and between the active drug and placebo. During the study, participants will undergo regular assessments including measurements of GA lesion size, visual function tests such as best corrected visual acuity under regular and low luminance, contrast sensitivity, and plasma drug levels. Safety is monitored through adverse event tracking from the first dose through month 19. The main outcome is the change in GA lesion area from baseline to month 18, with treatment effects and safety followed over this period.
1-10 of 17
1